Bionomics Limited Files Form 6-K with SEC

TL;DR

Bionomics (BNOX) filed a 6-K, confirming foreign issuer status and 20-F reporting. Standard update.

AI Summary

Bionomics Limited filed a Form 6-K on June 3, 2024, to report information to the SEC. The filing indicates the company is a foreign issuer and will file annual reports under Form 20-F. The company's principal executive office is located at 200 Greenhill Road, Eastwood SA 5063, Australia.

Why It Matters

This filing serves as an official notification to the SEC regarding Bionomics Limited's status as a foreign issuer and its reporting obligations, providing transparency for investors.

Risk Assessment

Risk Level: low — This filing is a routine administrative disclosure for a foreign issuer and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

• Bionomics Limited (company) — Registrant
• 200 Greenhill Road Eastwood SA 5063 (address) — Principal executive office
• June 3, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.99 — rrants, at a combined purchase price of $0.99 per ADS and Accompanying Warrant (or $0
• $0.9899 — 99 per ADS and Accompanying Warrant (or $0.9899 per Pre-Funded Warrant and Accompanying
• $0 — per ADS and Accompanying Warrant minus $0.0001, the exercise price of each Pre-Fu
• $7.5 million — regate gross proceeds to the Company of $7.5 million. · The second tranche of the
• $25.0 million — by the Investor of up to an additional $25.0 million of ADSs (or Pre-Funded Warrants in lieu
• $8.00 — ghted average price per ADS is at least $8.00 with an aggregate of at least $100 mill
• $100 million — ast $8.00 with an aggregate of at least $100 million in trading volume (or such lesser amoun
• $70.0 million — t to the Company would be approximately $70.0 million. Gross proceeds to the Company will be

Filing Documents

• bnox_6k_spa.htm (6-K) — 63KB
• bnox-ex99_1.htm (EX-99.1) — 356KB
• bnox-ex99_2.htm (EX-99.2) — 111KB
• bnox-ex99_3.htm (EX-99.3) — 137KB
• bnox-ex99_4.htm (EX-99.4) — 156KB
• bnox-ex99_5.htm (EX-99.5) — 22KB
• 0000950170-24-068125.txt ( ) — 847KB

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Securities Purchase Agreement, dated May 31, 2024, by and between the Company and the Investor 99.2 Registration Rights Agreement, dated June 3, 2024, by and between the Company and the Investor 99.3 Form of Pre-Funded Warran t 99.4 Form of Accompanying Warrant 99.5 Press release issued by the Company on May 31, 2024, furnished herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. Bionomics Limited (Registrant) By: /s/ Spyros Papapetropoulos Name: Spyros Papapetropoulos, MD Ph.D. Title: President & CEO Date: June 3, 2024

View Full Filing

View this 6-K filing on SEC EDGAR